Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
30. November 2022 14:08 ET
|
Biofrontera Inc.
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
21. November 2022 08:48 ET
|
Biofrontera Inc.
WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
31. Oktober 2022 08:55 ET
|
Biofrontera Inc.
Sets company up to realize full commercial potential in fast growing U.S. marketSupports mutually beneficial interests between Biofrontera Inc and Biofrontera AG WOBURN, Mass., Oct. 31, 2022 (GLOBE...
Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
14. Oktober 2022 08:40 ET
|
Biofrontera Inc.
WOBURN, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
12. Oktober 2022 14:00 ET
|
Biofrontera Inc.
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications...
Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
29. September 2022 10:04 ET
|
Biofrontera Inc.
WOBURN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
13. September 2022 08:30 ET
|
Biofrontera Inc.
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the...
Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence
09. Juni 2022 09:44 ET
|
Biofrontera Inc.
Named Among the 10 Fastest-Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine New Ameluz® Marketing Campaign Receives Gold 2022 Award of Excellence from The Communicator...
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
19. Mai 2022 09:48 ET
|
Biofrontera Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...
Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
08. April 2022 07:42 ET
|
Biofrontera Inc.
Introduces 2022 financial guidanceConference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a...